Stimulants, money, and recovery: how contingency management quietly became the most cost-effective treatment we have

There is no FDA-approved medication for methamphetamine use disorder. There is no FDA-approved medication for cocaine use disorder. The most active drug class in 70% of stimulant-involved overdose deaths is fentanyl, but the underlying stimulant use disorder doesn’t have a pill answer — and the field has spent twenty years looking for one.

What we do have is contingency management: a behavioral treatment in which a patient receives small, reliable financial rewards (typically gift cards or vouchers) for verified negative drug tests or attendance at treatment sessions. It is not new. The first randomized trials are from the 1990s. It has the strongest evidence base of any treatment for stimulant use disorder. And until 2025, it was effectively impossible to deliver at meaningful scale because federal anti-kickback rules capped the total annual incentive at $75 per patient — a value too low to produce the behavioral effect the trials had shown.

That changed in January 2025, when SAMHSA raised the cap ten-fold to $750 per patient per year. A new March 2026 cost-effectiveness paper in Addiction is the first modeling study to take the new cap seriously and put a price tag on what scaled CM would actually cost the health system.

The science: how contingency management works

Stimulant use disorder is, neurobiologically, a hijacking of the brain’s reward learning system. Methamphetamine and cocaine both produce massive, fast dopamine signals in the nucleus accumbens — far stronger and more rapid than natural rewards. Over time, the brain’s reward circuitry rewires to weight stimulant cues more strongly than alternative reinforcers (food, social connection, money, work).

Contingency management leverages the same reward learning that’s been hijacked. By providing a reliable, immediate, salient alternative reinforcer — money, often delivered the same day as a negative test — CM gives the brain another cue to learn against. It works best for stimulants because the alternative-reinforcement deficit is most severe in stimulant use disorder. It also works for opioids, alcohol, and tobacco, but the effect size is largest in stimulants.

The behavioral pharmacology is well-established. The bottleneck has always been delivery and policy.

The new cost-effectiveness data

The Addiction paper modeled two scenarios:

• A 12-week CM program prevented an estimated 117 deaths over one year in the modeled population, generated 0.70 lifetime quality-adjusted life years per person at an incremental cost of $6,850, for an incremental cost-effectiveness ratio (ICER) of $9,830 per QALY.
• A 24-week CM program prevented an estimated 153 deaths over one year, with 0.81 QALYs per person at an ICER of $12,312/QALY.

For context: the conventional U.S. willingness-to-pay threshold sits around $50,000–100,000 per QALY. A treatment at $9,830/QALY is, in cost-effectiveness terms, an extremely good deal. It’s roughly an order of magnitude more cost-effective than many widely covered cardiovascular and cancer therapies.

A separate 2025 American Journal of Psychiatry cohort study found CM-treated stimulant patients had lower mortality than matched comparators — adding observational evidence to the modeling.

The next frontier: smartphone-based CM

The $750 federal cap unlocks scale; smartphones might unlock access. A February 2026 JMIR Formative Research qualitative study examined patient and clinician acceptance of smartphone-based CM — where breath, saliva, or photo-verified test results trigger automatic gift-card disbursements. Both patients and clinicians found it acceptable; both flagged the same concerns: data privacy, the difficulty of verifying results without supervision, and the loss of the relational element when a counselor isn’t watching the test.

Digital CM is now the pattern most likely to reach the populations clinical CM has historically missed: rural communities, people who can’t take time off work for clinic visits, communities with provider deserts. It also raises a new design question — if the dispensed reinforcement is purely transactional, does it generalize? Early data suggest yes for stimulants in particular, but the long-term outcome research is still building.

Where the field disagrees

Three open arguments are worth knowing.

Is “paying for sobriety” ethical? Critics argue contingency management is paternalistic, that financial incentives are coercive in low-income populations, or that the model commodifies recovery. The clinical evidence on outcomes is unambiguous. The ethical debate continues, and most current implementations build in safeguards: the patient defines goals, payments are not contingent on disclosure of any other behavior, and the rewards are time-limited.

Does CM benefit generalize after rewards stop? Meta-analyses show effects diminish but persist after CM ends — better than placebo, weaker than during active treatment. Pairing CM with longer-term recovery community engagement appears to extend the effect.

Should CM be delivered as a medical benefit? The 2025 cap raise still leaves CM in a gray zone for many state Medicaid programs. Some states (California, Washington, Montana) have built it into their benefit; others have not. The SAMHSA cap removes the federal bar; state and payer adoption is now the rate-limiting step.

Resources

If you or a family member is dealing with methamphetamine use, ask treatment providers in your area whether they offer contingency management. State Medicaid coverage varies. The 2025 federal cap raise is now nine months old; many programs are still scaling up.

The 2025 federal cap raise is now nine months old; many programs are still scaling up.

Find a stimulant use disorder treatment provider near you →

If you are in crisis, call or text 988 for the Suicide & Crisis Lifeline. Methamphetamine-induced psychosis can be acute and frightening; ER care is appropriate when in doubt.